These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8974378)

  • 1. Ritanserin and alcohol abuse and dependence.
    Meert TF
    Alcohol Alcohol Suppl; 1994; 2():523-30. PubMed ID: 8974378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of 5-HT3 receptor antagonists in models of dependency and withdrawal.
    Costall B; Domeney AM; Kelly ME; Naylor RJ
    Alcohol Alcohol Suppl; 1993; 2():269-73. PubMed ID: 7748309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addiction and the potential for therapeutic drug development.
    Janssen PA
    EXS; 1994; 71():361-70. PubMed ID: 8032167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P rats develop physical dependence on alcohol via voluntary drinking: changes in seizure thresholds, anxiety, and patterns of alcohol drinking.
    Kampov-Polevoy AB; Matthews DB; Gause L; Morrow AL; Overstreet DH
    Alcohol Clin Exp Res; 2000 Mar; 24(3):278-84. PubMed ID: 10776663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ritanserin reduces abuse of alcohol, cocaine, and fentanyl in rats.
    Meert TF; Awouters F; Niemegeers CJ; Schellekens KH; Janssen PA
    Pharmacopsychiatry; 1991 Sep; 24(5):159-63. PubMed ID: 1775520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alcohol withdrawal syndrome: how to predict, prevent, diagnose and treat it.
    Prescrire Int; 2007 Feb; 16(87):24-31. PubMed ID: 17323538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ritanserin-induced changes in sleep-waking phases in rats.
    Kirov R; Moyanova S
    Acta Physiol Pharmacol Bulg; 1995; 21(4):87-92. PubMed ID: 8830880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressants attenuate both the enhanced ethanol intake and ethanol-induced anxiolytic effects in diazepam withdrawn rats.
    Martijena ID; Bustos SG; Bertotto ME; Molina VA
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):119-30. PubMed ID: 15572281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
    Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
    J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy reduces ethanol intake in an animal model of alcohol dependence.
    Ocaranza P; Quintanilla ME; Tampier L; Karahanian E; Sapag A; Israel Y
    Alcohol Clin Exp Res; 2008 Jan; 32(1):52-7. PubMed ID: 18070247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants.
    Ait-Daoud N; Malcolm RJ; Johnson BA
    Addict Behav; 2006 Sep; 31(9):1628-49. PubMed ID: 16472931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The High-Ethanol Preferring rat as a model to study the shift between alcohol abuse and dependence.
    Terenina-Rigaldie E; Jones BC; Mormède P
    Eur J Pharmacol; 2004 Nov; 504(3):199-206. PubMed ID: 15541422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acting out and psychoactive substances: alcohol, drugs, illicit substances].
    Gillet C; Polard E; Mauduit N; Allain H
    Encephale; 2001; 27(4):351-9. PubMed ID: 11686057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ritanserin in the treatment of alcohol dependence--a multi-center clinical trial. Ritanserin Study Group.
    Johnson BA; Jasinski DR; Galloway GP; Kranzler H; Weinreib R; Anton RF; Mason BJ; Bohn MJ; Pettinati HM; Rawson R; Clyde C
    Psychopharmacology (Berl); 1996 Nov; 128(2):206-15. PubMed ID: 8956382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Guidelines for the drug therapy of alcoholism].
    Gessa GL
    Recenti Prog Med; 1990 Mar; 81(3):171-5. PubMed ID: 2359869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated light-dark phase shifts modulate voluntary ethanol intake in male and female high alcohol-drinking (HAD1) rats.
    Clark JW; Fixaris MC; Belanger GV; Rosenwasser AM
    Alcohol Clin Exp Res; 2007 Oct; 31(10):1699-706. PubMed ID: 17681032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel uncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonist MRZ 2/579 suppresses ethanol intake in long-term ethanol-experienced rats and generalizes to ethanol cue in drug discrimination procedure.
    Hölter SM; Danysz W; Spanagel R
    J Pharmacol Exp Ther; 2000 Feb; 292(2):545-52. PubMed ID: 10640291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of high alcohol drinking in the inbred Fawn-Hooded (FH/Wjd) rat strain: implications for treatment.
    Overstreet DH; Rezvani AH; Cowen M; Chen F; Lawrence AJ
    Addict Biol; 2006 Sep; 11(3-4):356-73. PubMed ID: 16961764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ritanserin, a central 5-HT2 antagonist, in heavy social drinkers: desire to drink, alcohol intake and related effects.
    Naranjo CA; Poulos CX; Lanctôt KL; Bremner KE; Kwok M; Umana M
    Addiction; 1995 Jul; 90(7):893-905. PubMed ID: 7663312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of the 5-HT2 receptor antagonist, ritanserin, to alter preference for alcohol in drinking rats.
    Myers RD; Lankford MF
    Pharmacol Biochem Behav; 1993 May; 45(1):233-7. PubMed ID: 8516364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.